Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil

Detalhes bibliográficos
Autor(a) principal: Valentim,Joice
Data de Publicação: 2008
Outros Autores: Passos,Vanessa, Mataveli,Fabio, Calabró,Alessandra
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302008000900008
Resumo: This study aims to compare economic and patient impacts of the treatment of acromegaly with two different somatostatin analogues (octreotide LAR and lanreotide SR) in Brazil. A cost-effectiveness analysis was carried out under the Brazilian Public Health Care System (SUS) perspective. A decision analytical model was developed based on the Brazilian Public Health Care System Clinical Guideline for Acromegaly. A hypothetical cohort of 276 patients was followed for two years. Data were extracted from literature and administrative databases. Based on the analytical model, treatment with octreotide LAR would avoid 12 and 17 cases of GH and IGF-I elevated serum levels, respectively. Octreotide LAR was a cost-saving strategy, with net savings of R$10,448,324 (US$4,465,096) to SUS. Annual net savings per patient were R$ 18,928 (US$8,089). Treatment of acromegaly with octreotide LAR is a dominant strategy when compared to the treatment with lanreotide SR in Brazil. Sensitivity analysis did not alter the cost-saving status.
id SBEM-2_c214aa18aaf64d68bebf40f40ae40f98
oai_identifier_str oai:scielo:S0004-27302008000900008
network_acronym_str SBEM-2
network_name_str Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
repository_id_str
spelling Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in BrazilCost effectivenessAcromegalySomatostatin analoguesOctreotideLanreotideThis study aims to compare economic and patient impacts of the treatment of acromegaly with two different somatostatin analogues (octreotide LAR and lanreotide SR) in Brazil. A cost-effectiveness analysis was carried out under the Brazilian Public Health Care System (SUS) perspective. A decision analytical model was developed based on the Brazilian Public Health Care System Clinical Guideline for Acromegaly. A hypothetical cohort of 276 patients was followed for two years. Data were extracted from literature and administrative databases. Based on the analytical model, treatment with octreotide LAR would avoid 12 and 17 cases of GH and IGF-I elevated serum levels, respectively. Octreotide LAR was a cost-saving strategy, with net savings of R$10,448,324 (US$4,465,096) to SUS. Annual net savings per patient were R$ 18,928 (US$8,089). Treatment of acromegaly with octreotide LAR is a dominant strategy when compared to the treatment with lanreotide SR in Brazil. Sensitivity analysis did not alter the cost-saving status.Sociedade Brasileira de Endocrinologia e Metabologia2008-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302008000900008Arquivos Brasileiros de Endocrinologia & Metabologia v.52 n.9 2008reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.1590/S0004-27302008000900008info:eu-repo/semantics/openAccessValentim,JoicePassos,VanessaMataveli,FabioCalabró,Alessandraeng2009-02-02T00:00:00Zoai:scielo:S0004-27302008000900008Revistahttps://www.aem-sbem.com/ONGhttps://old.scielo.br/oai/scielo-oai.php||abem-editoria@endocrino.org.br1677-94870004-2730opendoar:2009-02-02T00:00Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false
dc.title.none.fl_str_mv Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
title Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
spellingShingle Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
Valentim,Joice
Cost effectiveness
Acromegaly
Somatostatin analogues
Octreotide
Lanreotide
title_short Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
title_full Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
title_fullStr Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
title_full_unstemmed Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
title_sort Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
author Valentim,Joice
author_facet Valentim,Joice
Passos,Vanessa
Mataveli,Fabio
Calabró,Alessandra
author_role author
author2 Passos,Vanessa
Mataveli,Fabio
Calabró,Alessandra
author2_role author
author
author
dc.contributor.author.fl_str_mv Valentim,Joice
Passos,Vanessa
Mataveli,Fabio
Calabró,Alessandra
dc.subject.por.fl_str_mv Cost effectiveness
Acromegaly
Somatostatin analogues
Octreotide
Lanreotide
topic Cost effectiveness
Acromegaly
Somatostatin analogues
Octreotide
Lanreotide
description This study aims to compare economic and patient impacts of the treatment of acromegaly with two different somatostatin analogues (octreotide LAR and lanreotide SR) in Brazil. A cost-effectiveness analysis was carried out under the Brazilian Public Health Care System (SUS) perspective. A decision analytical model was developed based on the Brazilian Public Health Care System Clinical Guideline for Acromegaly. A hypothetical cohort of 276 patients was followed for two years. Data were extracted from literature and administrative databases. Based on the analytical model, treatment with octreotide LAR would avoid 12 and 17 cases of GH and IGF-I elevated serum levels, respectively. Octreotide LAR was a cost-saving strategy, with net savings of R$10,448,324 (US$4,465,096) to SUS. Annual net savings per patient were R$ 18,928 (US$8,089). Treatment of acromegaly with octreotide LAR is a dominant strategy when compared to the treatment with lanreotide SR in Brazil. Sensitivity analysis did not alter the cost-saving status.
publishDate 2008
dc.date.none.fl_str_mv 2008-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302008000900008
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302008000900008
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-27302008000900008
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Endocrinologia e Metabologia
publisher.none.fl_str_mv Sociedade Brasileira de Endocrinologia e Metabologia
dc.source.none.fl_str_mv Arquivos Brasileiros de Endocrinologia & Metabologia v.52 n.9 2008
reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
instacron:SBEM
instname_str Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
instacron_str SBEM
institution SBEM
reponame_str Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
collection Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
repository.name.fl_str_mv Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
repository.mail.fl_str_mv ||abem-editoria@endocrino.org.br
_version_ 1754734810171965440